Achterbosch, Maria http://orcid.org/0000-0002-7304-2012
van de Hei, Susanne J. http://orcid.org/0000-0003-2844-6904
Dierick, Boudewijn J. H. http://orcid.org/0000-0001-6524-4290
Kocks, Janwillem W. H.
van den Berge, Maarten
Kerstjens, Huib A. M. http://orcid.org/0000-0001-7705-7927
Been-Buck, Sandra
Klemmeier, Titia
van Dijk, Liset
van Boven, Job F. M. http://orcid.org/0000-0003-2368-2262
Funding for this research was provided by:
Chiesi Farmaceutici (None)
Article History
Received: 17 October 2023
Accepted: 8 May 2024
First Online: 28 May 2024
Competing interests
: B.D. received consultancy fees from Chiesi, J.W.K. reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Chiesi, grants, personal fees and non-financial support from GSK, non-financial support from Mundi Pharma, grants and personal fees from Teva, personal fees from MSD, personal fees from COVIS Pharma, personal fees from ALK-Abello, grants from Valneva outside the submitted work; and J.W. K. holds <5% shares of Lothar Medtec GmbH and 72.5% of shares in the General Practitioners Research Institute. H.A.M.K. received grants and/or consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, and Trudell Medical, outside the submitted work and all paid to his institution. LvD received funding from TEVA Pharmaceuticals and Biogen for studies not related to this study. J.F.M.v.B. received a research grant from Chiesi paid to his institution for the study and reports grants and/or consultancy fees from ALK-Abello, AstraZeneca, Chiesi, European Commission COST (COST Action 19132), GSK, Novartis, Teva, Trudell Medical and Vertex, outside the submitted work and all paid to his institution. Other authors declare no competing interests.